

|  |                         |                    |                        |
|--|-------------------------|--------------------|------------------------|
| <b>TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT</b><br>(Under 37 CFR 1.97(b) or 1.97(c))  |                         |                    | Docket No.<br>NOV-0001 |
| In Re Application Of:    Chen  |                         |                    |                        |
| Serial No.<br>10/072,823   | Filing Date<br>2/8/2002 | Examiner<br>Meller | Group Art Unit<br>1654 |
| Title:    ANTI-CANCER AGENTS AND METHODS OF USE THEREOF  |                         |                    |                        |
| <div style="text-align: center;">           Address to:<br/> <b>Commissioner for Patents</b><br/> <b>P.O. Box 1450</b><br/> <b>Alexandria, VA 22313-1450</b> </div> <div style="text-align: center; margin-top: 10px;"> <b>37 CFR 1.97(b)</b> </div> <p>1.    <input checked="" type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.</p> <div style="text-align: center; margin-top: 20px;"> <b>37 CFR 1.97(c)</b> </div> <p>2.    <input type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:</p> <div style="margin-left: 40px; margin-top: 10px;"> <input type="checkbox"/> the statement specified in 37 CFR 1.97(e);         </div> <div style="text-align: center; margin-top: 10px;"> <b>OR</b> </div> <div style="margin-left: 40px; margin-top: 10px;"> <input type="checkbox"/> the fee set forth in 37 CFR 1.17(p).         </div> |                         |                    |                        |

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.  
NOV-0001

In Re Application: Chen

Serial No.  
10/072,823

Filing Date  
2/8/2002

Examiner  
Meller

Group Art Unit  
1654

**ANTI-CANCER AGENTS AND METHODS OF USE THEREOF**

**Payment of Fee**

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of \_\_\_\_\_ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. **06-1130**  
as described below.
- ☐ Charge the amount of \_\_\_\_\_
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.

**Certificate of Transmission by Facsimile\***

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (F:

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

**Certificate of Mailing by First Class Mail**

I certify that this document and fee is being deposited on **11/14/2003** with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

*Rebecca L. Blake*  
Signature of Person Mailing Correspondence

Rebecca L. Blake

Typed or Printed Name of Person Mailing Certificate

\*This certificate may only be used if paying by deposit account.

*J. Michael Buchanan*  
Signature

Dated: November 14, 2003

J. Michael Buchanan

Registration No. 44,571

Customer No. 23413

Telephone No. 860-286-2929

CC:

|   |  |   |   |
|---|--|---|---|
| <b>INFORMATION DISCLOSURE CITATION</b><br>(Use several sheets if necessary) |  | Docket Number (Optional)<br><b>NOV-0001</b> | Application Number<br><b>10/072,823</b> |
|   |  | Applicant(s)<br><b>Sophie Chen</b>          | Filing Date<br><b>2/8/2002</b>          |
|   |  | Group Art Unit<br><b>1654</b>               |   |
| *EXAMINER<br>INITIAL  | OTHER DOCUMENTS (Including Author's File, Date, Pertinent Pages, Etc.)   |   |   |
|   | Sophie Chen, "In Vitro Mechanism of PC SPES", Urology (2001) 58(Supplement 2A) 28-35   |   |   |
|   | William K. Oh et al., "Activity of the Herbal Combination, PC-SPES, in the Treatment of Patients with Adrogen-Independent Prostate Cancer, Urology (2001) 57(1): 122-126                                 |   |   |
|   | Hank Porterfield, "UsToo PC-SPES Surveys: Review of Studies and Update of Previous Survey Results", Molecular Urology, Volume 4, Number 3, 2000, pp. 289-291   |   |   |
|   | B. L. Pfeifer et al., "PC-SPES, A Dietary Supplement for the Treatment of Hormone-Refractory Prostate Cancer", BJU International (2000), 85, 481-485   |   |   |
|   | Eric J. Small et al., "Prospective Trial of the Herbal Supplement PC-SPES in Patients with Progressive Prostate Cancer", Journal of Clinical Oncology, Vol. 18, No. 21 (November 1), 2000: pp. 3595-3603 |   |   |
|   | Ikezoe et al., "Oridonin Induces Growth Inhibition and Apoptosis of a Variety of Human Cancer Cells", Int. J. Oncol.23: 1187-1193, 2003  |   |   |
|   |  |   |   |
|   |  |   |   |
|   |  |   |   |
|   |  |   |   |
|   |  |   |   |
|   |  |   |   |
|   |  |   |   |
| EXAMINER  |  | DATE CONSIDERED                             |   |

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.